CBIO vs CBUS

Crescent Biopharma, Inc. vs Cibus, Inc. — Valuation Comparison 2026

CBIO

Biotechnology
Crescent Biopharma, Inc.
Quality
5.3
out of 10
Value Trap
12
SAFE
Price
$21.47
Last close
Models
9/13
Active
VS

CBUS

Biotechnology
Cibus, Inc.
Quality
5.7
out of 10
Value Trap
33
LOW
Price
$1.45
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CBIO Fair ValueCBIO Upside CBUS Fair ValueCBUS Upside
Bayesian DCF Intrinsic $8.97 -58.2% $0.39 -73.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $4.01 -81.3% $2.01 +38.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CBIO vs CBUS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CBIO vs CBUS — Which Stock Is More Undervalued?

CBUS scores higher with a 5.7/10 quality rating vs CBIO's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Crescent Biopharma, Inc. (CBIO) and Cibus, Inc. (CBUS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CBIO currently trades at $21.47 with a QOC of 5.3/10, while CBUS trades at $1.45 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).